{"id":"afrezza-plus-one-drop-premium","safety":{"commonSideEffects":[{"rate":"27","effect":"Cough"},{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Throat irritation"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL3394706","moleculeType":"Small molecule","molecularWeight":"311.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Afrezza uses a proprietary pulmonary delivery system to administer human insulin as a dry powder that is inhaled and absorbed through the respiratory tract. This allows for faster insulin onset compared to subcutaneous injection, with peak levels reached in approximately 12-15 minutes. The One Drop integration provides digital glucose monitoring and insulin dosing guidance to optimize glycemic control.","oneSentence":"Afrezza is a rapid-acting inhaled insulin that delivers insulin directly to the lungs for quick absorption into the bloodstream to lower blood glucose.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:42:09.165Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03313960","phase":"PHASE4","title":"A Randomized Controlled Trial Evaluating One Drop | Premium With Afrezza vs. One Drop | Premium Alone","status":"UNKNOWN","sponsor":"Informed Data Systems, Inc.","startDate":"2017-10-05","conditions":"Diabetes Mellitus, Type 2","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5836,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["insulin inhalation"],"phase":"marketed","status":"active","brandName":"Afrezza plus One Drop | Premium","genericName":"Afrezza plus One Drop | Premium","companyName":"Informed Data Systems, Inc.","companyId":"informed-data-systems-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Afrezza is being studied in combination with One Drop | Premium for the treatment of Type 2 Diabetes Mellitus. A randomized controlled trial, NCT03313960, is evaluating the effectiveness of Afrezza plus One Drop | Premium compared to One Drop | Premium alone.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}